ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2510

The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis

Francis Lao1, Cal Robinson2, Dorota Borovski3, KAREN BEATTIE4, Joycelyne Ewusie5, Rahul Chanchlani3 and Michelle Batthish6, 1The Hospital for Sick Children, Hamilton, ON, Canada, 2The Hospital for Sick Children, Toronto, ON, Canada, 3McMaster University, Hamilton, Canada, 4McMaster University, Hamilton, ON, Canada, 5McMaster University, Hamilton, 6McMaster Children's Hospital, Hamilton, ON, Canada

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, meta-analysis, Pediatric rheumatology, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Kawasaki Disease (KD) is a common childhood vasculitis. Coronary artery aneurysms (CAAs) develop in approximately 25% of untreated KD patients. However, there is limited data on the long-term cardiovascular events following childhood KD diagnosis, especially in the post-IVIG era. We aimed to determine the cumulative incidence and incidence rate of myocardial infarction (MI), heart failure (HF), and cardiac arrest, referred to as cardiovascular events and mortality following KD diagnosis.

Methods: We performed a literature search using 5 databases until 2022. We retrieved English articles for review including randomized-controlled trials, cross-sectional studies, case-control studies, cohort studies, and abstracts. The search produced 181 full-text articles for data extraction (Figure 1). The Newcastle-Ottawa Scale assessed study quality focusing on participant selection, comparability, and measurement of outcome or ascertainment of exposure. The study was submitted to PROSPERO on 23 November 2019 and registered on 28 April 2020.

Results: Among 392,848 KD patients across 181 studies, there were 1548 and 1090 cases of cardiovascular events (MI, heart failure, or cardiac arrest) and death, respectively. The median follow-up period of studies included was 60 months. Meta-analysis generated a cumulative incidence of cardiovascular events of 0.85% and death of 0.24%. Subgroup analysis for CAA presence and IVIG use was performed. Among studies where all participants had CAAs, the cumulative incidence was 3.5% and 0.99% for cardiovascular events and death, respectively. For studies where none or few of the participants had CAAs, the cumulative incidence was 0.02% and 0.03% for cardiovascular events and death, respectively (Figure 2). Among studies where all participants received IVIG, the cumulative incidence was 0.05% and 0.14% for cardiovascular events and death, respectively. For studies where none or few of the participants received IVIG the cumulative incidence was 2.3% and 0.63% for cardiovascular events and death, respectively (Figure 3).

Conclusion: This study comprises the largest systematic review and meta-analysis of long-term cardiovascular outcomes and mortality following childhood KD diagnosis. The low prevalence of mortality (< 1%) and lower prevalence of cardiovascular events for patients without CAAs can provide reassurance to families. Those with CAAs, however, have higher prevalence of cardiovascular events which highlights the need for CAA surveillance, monitoring, and potential intervention to prevent development of these events. Further studies are needed to better define the risk of long-term cardiovascular events and mortality following childhood KD diagnosis.

Supporting image 1

PRISMA diagram

Supporting image 2

Cumulative incidence of cardiovascular events and all-cause mortality by CAA status. A subgroup analysis was performed, stratifying studies by CAA status of participants: all patients with CAA (100% of study participants) and no/few CAA (≤ 10% of study participants).

Supporting image 3

Cumulative incidence of cardiovascular events and mortality by IVIG treatment status. A subgroup analysis was performed, stratifying studies by IVIG treatment status of participants: all patients received IVIG (100% of study participants) and no/few patients received IVIG (≤10% of study participants).


Disclosures: F. Lao: None; C. Robinson: None; D. Borovski: None; K. BEATTIE: None; J. Ewusie: None; R. Chanchlani: None; M. Batthish: Abbvie, 6, Novartis, 2, Viatris, 12, Unrestricted Educational Grant.

To cite this abstract in AMA style:

Lao F, Robinson C, Borovski D, BEATTIE K, Ewusie J, Chanchlani R, Batthish M. The Effect of Coronary Artery Aneurysms and IVIG Use on Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review and Meta-analysis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-effect-of-coronary-artery-aneurysms-and-ivig-use-on-long-term-cardiovascular-disease-and-mortality-following-kawasaki-disease-in-childhood-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-coronary-artery-aneurysms-and-ivig-use-on-long-term-cardiovascular-disease-and-mortality-following-kawasaki-disease-in-childhood-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology